Hexima Limited (HXL.AX)
AUD 0.01
(0.0%)
AUD 0.01
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 | -933.87 Thousand AUD | 51.33% |
| 2023 | -1.91 Million AUD | 80.85% |
| 2022 | -10.02 Million AUD | -45.79% |
| 2021 | -6.87 Million AUD | -89.58% |
| 2020 | -3.62 Million AUD | -25.22% |
| 2019 | -2.89 Million AUD | -48.4% |
| 2018 | -1.95 Million AUD | -5.12% |
| 2017 | -1.85 Million AUD | 4.27% |
| 2016 | -1.93 Million AUD | 6.88% |
| 2015 | -2.08 Million AUD | 14.23% |
| 2014 | -2.42 Million AUD | 14.81% |
| 2013 | -2.84 Million AUD | 0.0% |
| 2010 | -6.11 Million AUD | 45.73% |
| 2009 | -11.27 Million AUD | -272.16% |
| 2008 | -3.02 Million AUD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -192.38 Thousand AUD | 47.78% |
| 2024 FY | -933.87 Thousand AUD | 51.33% |
| 2024 Q4 | -549.1 Thousand AUD | 0.0% |
| 2024 Q2 | -384.76 Thousand AUD | -100.0% |
| 2023 Q1 | -775.23 Thousand AUD | 87.01% |
| 2023 FY | -1.91 Million AUD | 80.85% |
| 2023 Q4 | -368.41 Thousand AUD | -100.0% |
| 2023 Q3 | -184.2 Thousand AUD | 88.12% |
| 2023 Q2 | -1.55 Million AUD | -100.0% |
| 2022 FY | -10.02 Million AUD | -45.79% |
| 2022 Q3 | -2.98 Million AUD | 26.35% |
| 2022 Q4 | -5.96 Million AUD | -100.0% |
| 2022 Q2 | -4.05 Million AUD | -100.0% |
| 2022 Q1 | -2.02 Million AUD | 51.08% |
| 2021 Q4 | -4.14 Million AUD | -100.0% |
| 2021 Q1 | -1.36 Million AUD | 25.59% |
| 2021 FY | -6.87 Million AUD | -89.58% |
| 2021 Q2 | -2.73 Million AUD | -100.0% |
| 2021 Q3 | -2.07 Million AUD | 24.21% |
| 2020 Q2 | -1.78 Million AUD | -100.0% |
| 2020 Q3 | -917.88 Thousand AUD | 48.72% |
| 2020 Q4 | -1.83 Million AUD | -100.0% |
| 2020 FY | -3.62 Million AUD | -25.22% |
| 2020 Q1 | -894.99 Thousand AUD | 54.72% |
| 2019 Q3 | -988.2 Thousand AUD | -115.03% |
| 2019 Q1 | -459.56 Thousand AUD | 13.46% |
| 2019 FY | -2.89 Million AUD | -48.4% |
| 2019 Q2 | -459.56 Thousand AUD | 0.0% |
| 2019 Q4 | -1.97 Million AUD | -100.0% |
| 2018 Q2 | -444.55 Thousand AUD | 0.0% |
| 2018 Q1 | -444.55 Thousand AUD | 7.84% |
| 2018 FY | -1.95 Million AUD | -5.12% |
| 2018 Q4 | -531.05 Thousand AUD | 0.0% |
| 2018 Q3 | -531.05 Thousand AUD | -19.46% |
| 2017 Q2 | -445.73 Thousand AUD | 0.0% |
| 2017 Q4 | -482.36 Thousand AUD | 0.0% |
| 2017 Q3 | -482.36 Thousand AUD | -8.22% |
| 2017 FY | -1.85 Million AUD | 4.27% |
| 2017 Q1 | -445.73 Thousand AUD | 21.93% |
| 2016 Q2 | -398.59 Thousand AUD | 0.0% |
| 2016 FY | -1.93 Million AUD | 6.88% |
| 2016 Q1 | -398.59 Thousand AUD | -34.8% |
| 2016 Q4 | -570.91 Thousand AUD | 0.0% |
| 2016 Q3 | -570.91 Thousand AUD | -43.23% |
| 2015 Q2 | -745.46 Thousand AUD | 0.0% |
| 2015 Q1 | -745.46 Thousand AUD | -45.72% |
| 2015 FY | -2.08 Million AUD | 14.23% |
| 2015 Q4 | -295.69 Thousand AUD | 0.0% |
| 2015 Q3 | -295.69 Thousand AUD | 60.33% |
| 2014 Q4 | -511.58 Thousand AUD | 0.0% |
| 2014 Q3 | -511.58 Thousand AUD | 27.16% |
| 2014 Q2 | -702.34 Thousand AUD | 0.0% |
| 2014 Q1 | -702.34 Thousand AUD | -10.7% |
| 2014 FY | -2.42 Million AUD | 14.81% |
| 2013 Q2 | -790.46 Thousand AUD | 0.0% |
| 2013 FY | -2.84 Million AUD | 0.0% |
| 2013 Q3 | -634.48 Thousand AUD | 19.73% |
| 2013 Q1 | -790.46 Thousand AUD | 0.0% |
| 2013 Q4 | -634.48 Thousand AUD | 0.0% |
| 2010 FY | -6.11 Million AUD | 45.73% |
| 2009 FY | -11.27 Million AUD | -272.16% |
| 2008 FY | -3.02 Million AUD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| AdAlta Limited | -5.38 Million AUD | 82.646% |
| Acrux Limited | -5.8 Million AUD | 83.899% |
| Actinogen Medical Limited | -13.04 Million AUD | 92.841% |
| AnteoTech Limited | -8.88 Million AUD | 89.484% |
| Argenica Therapeutics Limited | -5.47 Million AUD | 82.957% |
| Arovella Therapeutics Limited | -8.74 Million AUD | 89.322% |
| Anatara Lifesciences Ltd | -1.45 Million AUD | 35.65% |
| Alterity Therapeutics Limited | -19.12 Million AUD | 95.117% |
| Amplia Therapeutics Limited | -4.5 Million AUD | 79.263% |
| Avecho Biotechnology Limited | -3.43 Million AUD | 72.825% |
| Bio-Gene Technology Limited | -2.4 Million AUD | 61.237% |
| Biome Australia Limited | -1.67 Million AUD | 44.086% |
| Biotron Limited | -3.43 Million AUD | 72.825% |
| Botanix Pharmaceuticals Limited | -13.86 Million AUD | 93.267% |
| BTC Health Limited | 1.05 Million AUD | 188.495% |
| Chimeric Therapeutics Limited | -12.52 Million AUD | 92.547% |
| CSL Limited | 2.64 Billion AUD | 100.035% |
| Clarity Pharmaceuticals Ltd | -42.32 Million AUD | 97.794% |
| Clinuvel Pharmaceuticals Limited | 35.63 Million AUD | 102.621% |
| Cynata Therapeutics Limited | -9.74 Million AUD | 90.417% |
| Dimerix Limited | -17.07 Million AUD | 94.531% |
| EZZ Life Science Holdings Limited | 6.96 Million AUD | 113.409% |
| Island Pharmaceuticals Limited | -2.86 Million AUD | 67.396% |
| Immuron Limited | -6.93 Million AUD | 86.538% |
| Immutep Limited | -39.89 Million AUD | 97.659% |
| Imugene Limited | -149.68 Million AUD | 99.376% |
| Invex Therapeutics Ltd | -1.64 Million AUD | 43.119% |
| Memphasys Limited | -4.44 Million AUD | 78.976% |
| Nanollose Limited | -1.15 Million AUD | 19.254% |
| Neuren Pharmaceuticals Limited | 157.08 Million AUD | 100.595% |
| Noxopharm Limited | -3.57 Million AUD | 73.9% |
| NeuroScientific Biopharmaceuticals Limited | 324.21 Thousand AUD | 388.046% |
| Nyrada Inc. | -1.38 Million AUD | 32.632% |
| Orthocell Limited | -7.18 Million AUD | 86.995% |
| PharmAust Limited | -9.03 Million AUD | 89.661% |
| Patrys Limited | -3.53 Million AUD | 73.613% |
| Paradigm Biopharmaceuticals Limited | -58.65 Million AUD | 98.408% |
| Proteomics International Laboratories Limited | -6.37 Million AUD | 85.354% |
| Prescient Therapeutics Limited | -8.23 Million AUD | 88.664% |
| PYC Therapeutics Limited | -37.72 Million AUD | 97.525% |
| Race Oncology Limited | -13.81 Million AUD | 93.242% |
| Radiopharm Theranostics Limited | -47.94 Million AUD | 98.052% |
| Recce Pharmaceuticals Ltd | -17.66 Million AUD | 94.712% |
| Starpharma Holdings Limited | -8.16 Million AUD | 88.562% |
| Telix Pharmaceuticals Limited | 5.21 Million AUD | 117.921% |
| Tissue Repair Ltd | -4.13 Million AUD | 77.432% |
| Zelira Therapeutics Limited | -36.56 Million AUD | 97.446% |